Editorial comment.
Gonzalgo
Mark L
ML
Department of Urology, Stanford University School of Medicine, Stanford, California, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000925:Anticoagulants / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D000077144:Clopidogrel; D004347:Drug Interactions; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014859:Warfarin / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000925:Anticoagulants; D001500:BCG Vaccine; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin